RogerBlack
Senior Member
- Messages
- 902
http://www.nature.com/tp/journal/v6/n9/full/tp2016184a.html
"Bottom-up proteomics suggests an association between differential expression of mitochondrial proteins and chronic fatigue syndrome."
Is potentially interesting.
They took two twins, with and without CFS, and analysed the proteins found in the mitochondria.
This is different from the DNA - the proteins tell you what the genes are actually doing.
They analysed the differences and found three candidate marker proteins that are found in the mitochondria of platelet cells in blood - based on differences between the two twins.
They then went on to measure these three proteins in a cohort of 50 people with and 50 without CFS (Fuduka criteria). The test in this group was done on saliva.
"The selected proteins were as follows: aconitate hydratase (ACON), ATP synthase subunit beta (ATPB) and malate dehydrogenase (MDHM)."
I stalled out partway through the analysis section, but my understanding is that this is an interesting test - which is great for 'proving it's a real disease' - but seems not to find all CFS patients.
For the FACIT criteria - "sensitivity=93% and specificity=70%" - which is really pretty good.
As I understand it, the three proteins chosen were chosen from a subset of the ones they could have looked at, as these three proteins were thought likely to be an issue.
it may be that adding more proteins would help in discrimination, or finding disparate patient populations with variants of cfs.
"Bottom-up proteomics suggests an association between differential expression of mitochondrial proteins and chronic fatigue syndrome."
Is potentially interesting.
They took two twins, with and without CFS, and analysed the proteins found in the mitochondria.
This is different from the DNA - the proteins tell you what the genes are actually doing.
They analysed the differences and found three candidate marker proteins that are found in the mitochondria of platelet cells in blood - based on differences between the two twins.
They then went on to measure these three proteins in a cohort of 50 people with and 50 without CFS (Fuduka criteria). The test in this group was done on saliva.
"The selected proteins were as follows: aconitate hydratase (ACON), ATP synthase subunit beta (ATPB) and malate dehydrogenase (MDHM)."
I stalled out partway through the analysis section, but my understanding is that this is an interesting test - which is great for 'proving it's a real disease' - but seems not to find all CFS patients.
For the FACIT criteria - "sensitivity=93% and specificity=70%" - which is really pretty good.
As I understand it, the three proteins chosen were chosen from a subset of the ones they could have looked at, as these three proteins were thought likely to be an issue.
it may be that adding more proteins would help in discrimination, or finding disparate patient populations with variants of cfs.
Last edited: